Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RPR's LOVENOX BLEEDING COMPARED WITH COUMADIN IN 74-PATIENT STUDY

Executive Summary

RPR's LOVENOX BLEEDING COMPARED WITH COUMADIN IN 74-PATIENT STUDY conducted to examine cost-effectiveness of the two anticoagulants at an Ohio hospital. The study was presented Dec. 7 at the American Society of Hospital Pharmacists mid-year meeting in Miami Beach. Pharmacist Kelly Konz compared Rhone-Poulenc Rorer's Lovenox (enoxaparin) and DuPont-Merck's Coumadin (warfarin) "in terms of relevant costs from a hospital perspective and outcomes of prophylaxis following hip replacement surgery" for deep vein thrombosis and pulmonary embolism. Konz conducted the study at Grant Medical Center, a 640-bed private teaching hospital.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel